XOMA Royalty adds milestone and royalty economics associated with two partnered assetsEMERYVILLE, Calif. and UTRECHT, The ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

LAVA Therapeutics N.V. (NASDAQ:LVTX) saw its stock rise 4.2% following news of a share purchase agreement with XOMA Royalty ...

Fintel reports that on August 5, 2025, Jefferies downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX) from Buy ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

Xoma Royalty has agreed to acquire Lava Therapeutics.

LAVA Therapeutics (LVTX) stock gains as XOMA Royalty (XOMA) agrees to acquire the company for up to $1.24/share plus contingent value rights. Read more here.

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

Under the terms of the agreement, XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) representing 75% of net proceeds ...

In a separate transaction, XOMA Royalty will acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, plus a CVR representing the right to receive 75% of net proceeds related to LAVA’s ...

LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the ...

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for ...